SCHEMBL20599894

SCHEMBL20599894

O=C(O)C(=CNc1cccnc1-c1cc(Cl)cc(Cl)c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 3/20 0.42
▸ KCNN4 O15554 1/20 0.42
▸ JAK2 O60674 1/20 0.39
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ KCND3 Q9UK17 1/20 0.38
▸ RORB Q92753 1/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDR P35968 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35
▸ KMO O15229 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20621799 0.82 MAPT (0.56) GAAMAPTALDH1A1LMNAMEN1
SCHEMBL18984723 0.79 MAPT (0.52) NPC1RAB9AL3MBTL1GAAMAPT
SCHEMBL20600156 0.77 RXFP1 (0.41) KCNA5NPC1RAB9AGAAKDR
SCHEMBL20599776 0.74 GSK3B (0.39) KCNA5MAPTALDH1A1LMNAMEN1
SCHEMBL21922487 0.72 MAPT (0.40) KCNA5KCNN4NPC1RAB9AKCND3
SCHEMBL11804826 0.66 LMNA (0.52) NPC1RAB9AL3MBTL1GAAMAPT
SCHEMBL1860954 0.66 TRIM24 (0.46) KCNA5KCNN4NPC1RAB9AKCND3
SCHEMBL11129959 0.66 LMNA (0.37) NPC1RAB9AL3MBTL1GAAMAPT
SCHEMBL11768825 0.65 MAPT (0.47) NPC1RAB9AL3MBTL1MAPTALDH1A1
SCHEMBL9005346 0.64 RAB9A (0.55) NPC1RAB9AL3MBTL1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615527-B1 NEW AZAQUINOLINE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2024-03-06 — — EP disclosed
US-11485733-B2 Azaquinoline derivatives BAYER ANIMAL HEALTH GMBH (DE) 2022-11-01 — — US disclosed
US-20200131175-A1 NEW AZAQUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-04-30 — — US disclosed
EP-3615527-A1 NEW AZAQUINOLINE DERIVATIVES Bayer Animal Health GmbH (DE) 2020-03-04 — — EP disclosed
WO-2019002132-A1 NEW AZAQUINOLINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131175-A1 NEW AZAQUINOLINE DERIVATIVES RECQL, H1-5, CHRM1 KCNA5 564/4885KCNN4 3549/4885JAK2 1137/4885
US-11485733-B2 Azaquinoline derivatives RECQL, H1-5, H1-3 KCNA5 882/4885KCNN4 3186/4885JAK2 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback